ATC kodas
L01E: Protein kinase inhibitors
Vaistiniai preparatai
357
Kompensuojami
106
Tiekimo sutrikimai
24
Pogrupiai
L01EA: Bcr-abl tyrosine kinase inhibitorsL01EB: Epidermal growth factor receptor (egfr) tyrosine kinase inhibitorsL01EC: B-raf serine-threonine kinase (braf) inhibitorsL01ED: Anaplastic lymphoma kinase (alk) inhibitorsL01EE: Mitogen-activated protein kinase (mek) inhibitorsL01EF: Cyclin-dependent kinase (cdk) inhibitorsL01EG: Mammalian target of rapamycin (mtor) kinase inhibitorsL01EH: Human epidermal growth factor receptor 2 (her2) tyrosine kinase inhibitorsL01EJ: Janus-associated kinase (jak) inhibitorsL01EK: Vascular endothelial growth factor receptor (vegfr) tyrosine kinase inhibitorsL01EL: Bruton's tyrosine kinase (btk) inhibitorsL01EM: Phosphatidylinositol-3-kinase (pi3k) inhibitorsL01EN: Fibroblast growth factor receptor (fgfr) tyrosine kinase inhibitorsL01EX: Other protein kinase inhibitors
Vaistiniai preparatai
Forma
Stiprumas
Veiklioji medžiaga
Gamintojas
Kompensuojami
Rūšiuoti pagal:
Afatinibas, 50 mg
Boehringer Ingelheim International GmbH
Netiekiama
Receptinis
-
Imatinibas, 100 mg
Novartis Europharm Ltd.
Netiekiama
Receptinis
-
Imatinibas, 400 mg
Novartis Europharm Ltd.
Netiekiama
Receptinis
-
Ponatinibas, 5 mg
Incyte Biosciences Distribution B.V.
Netiekiama
Receptinis
-
Ponatinibas, 45 mg
Incyte Biosciences Distribution B.V.
Netiekiama
Receptinis
-
Ponatinibas, 30 mg
Incyte Biosciences Distribution B.V.
Netiekiama
Receptinis
-
Ponatinibas, 15 mg
Incyte Biosciences Distribution B.V.
Netiekiama
Receptinis
-
Ibrutinibas, 280 mg
Janssen-Cilag International N.V.
Netiekiama
Receptinis
-
Ibrutinibas, 140 mg
Janssen-Cilag International N.V.
Netiekiama
Receptinis
-